MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Infectious Disease_Hepatitis
Hepion Pharmaceuticals, Inc. (HEPA), formerly, ContraVir Pharmaceuticals (CTRV)*
Organization & Developments: ContraVir
Parents
Hepion Pharmaceuticals, Inc. (HEPA), formerly, ContraVir Pharmaceuticals (CTRV)*
Children
2018: ContraVir is developing a portfolio of novel compounds against hepatitis B, including TXL™, a highly potent prodrug of the antiviral tenofovir (active component of both Vemlidy® and Viread®), now in Phase 2 trials, and CRV431, a next generation cyclophilin inhibitor advancing into clinical development.
2019: ContraVir And CRV431 In NASH: An Update - ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV)
2020: Hepion Pharmaceuticals: CRV431 Continues To Progress In Early Phase NASH Clinical Trials
ContraVir Pharmaceuticals, Inc. operates as a subsidiary of Synergy Pharmaceuticals, Inc.
Hepion Pharmaceuticals, Inc (NASDAQ: HEPA) is a biopharmaceutical company focused on the development of drug therapy for treatment of chronic liver diseases.
Hepion’s cyclophilin inhibitor, Rencofilstat (formerly CRV431), is developed to address multiple pathologies related to advanced liver disease.
Jumps
*Key People: ContraVir
Finance & Acquisitions: ContraVir